Trump-Touted Malaria Drug Fails in Covid-19 Study
This article is for subscribers only.
A malaria drug that was touted by U.S. President Donald Trump and widely used as a potential treatment for patients with Covid-19 failed to help those with infections stay off ventilators or live longer, according to a study published in the New England Journal of Medicine.
Researchers at New York-Presbyterian Hospital and Columbia University Irving Medical Center in New York City evaluated 1,376 consecutive patients who showed up at the emergency room with symptoms of coronavirus, comparing the fate of those who received the medication, hydroxychloroquine, to those who didn’t. Nearly 60% of the patients were given the drug, typically within 48 hours, and they were more sick on average.